tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robert Willoughby, 23 are a BUY (58.97%), 14 are a HOLD (35.9%), 2 are a SELL (5.13%).
Analyst Robert Willoughby, currently employed at CREDIT SUISSE, carries an average stock price target met ratio of 53.81% that have a potential upside of 14.99% achieved within 144 days.
Robert Willoughby’s has documented 94 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MCK, McKesson at 08-Aug-2022.
Analyst best performing recommendations are on DPLO (DIPLOMAT PHARMACY).
The best stock recommendation documented was for ALGN (ALIGN TECHNOLOGY) at 4/28/2017. The price target of $140 was fulfilled within 6 days with a profit of $5.38 (4%) receiving and performance score of 6.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$275
$48.08 (21.19%)
$285
29 days ago
(24-Oct-2024)
27/38 (71.05%)
$58.58 (27.07%)
149
Buy
$250
$23.08 (10.17%)
$270
29 days ago
(24-Oct-2024)
5/11 (45.45%)
$33.58 (15.52%)
273
Buy
$275
$48.08 (21.19%)
$285
29 days ago
(24-Oct-2024)
14/33 (42.42%)
$58.58 (27.07%)
93
Buy
$276
$49.08 (21.63%)
$325
29 days ago
(24-Oct-2024)
21/29 (72.41%)
$59.58 (27.53%)
97
Hold
$320
$93.08 (41.02%)
$260
7 months 7 days ago
(15-Apr-2024)
8/14 (57.14%)
$15.26 (5.01%)
142
What Year was the first public recommendation made by Robert Willoughby?
